About: http://data.cimple.eu/news-article/d88632c37696ce9be2b43bae7e49d068f1f24930d912e9939944c7a6

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/d88632c37696ce9be2b43bae7e49d068f1f24930d912e9939944c7a6 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The first human trial to evaluate a candidate vaccine against coronavirus disease 2019 has begun in Seattle, US health officials said Monday. "The open-label trial will enroll 45 healthy adult volunteers ages 18 to 55 years over approximately 6 weeks," the US National Institutes of Health (NIH) said in a statement. "The first participant received the investigational vaccine today." But the candidate would still need to progress through various more stages, known as phases, to prove it works and is safe. US officials have estimated it may take another year to 18 months before it becomes available -- if everything goes to plan. The vaccine is called mRNA-1273 and was developed by NIH scientists and collaborators at biotechnology company Moderna, which is based in Cambridge, Massachusetts. Funding was also provided by the Oslo-based Coalition for Epidemic Preparedness Innovations (CEPI). "Finding a safe and effective vaccine to prevent infection with SARS-CoV-2 is an urgent public health priority," said Anthony Fauci, head of infectious diseases at the NIH. "This Phase 1 study, launched in record speed, is an important first step toward achieving that goal." Coronaviruses are spherical and have spikes protruding from their surface, giving them a crown-like appearance. The spike binds to human cells, allowing the virus to gain entry. The Moderna candidate vaccine carries the genetic information of this spike in a substance called "messenger RNA." Injecting human tissue with the spike's messenger RNA makes it grow inside the body, thereby eliciting an immune response without having actually infected a person with the full-blown virus. ia/ft
schema:headline	US begins first human trial of coronavirus vaccine
schema:mentions	Biotechnology 18 Months National Institutes of Health Seattle Public health Massachusetts Ia (cuneiform) Anthony S. Fauci Messenger RNA Virus Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Open-label trial
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-03-16 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	77 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software